EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of [ 111 In]octreotide Scintigraphy and [ 68 Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility

Roberto Fedrigo, Sara Harsini, Luke Murtha, Joao Paulo Solar Vasconcelos, Carlos Uribe, Don Wilson, Francois Benard, Ian Alberts, Patrick Martineau, Jonathan M Loree

Neuroendocrinology · 12.06.2026 · 1-8

DOI: 10.1159/000552968 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Neuroendocrinology, online erschienen am 12.06.2026. Verfasst von Roberto Fedrigo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Pancreatic Neoplasms, Positron-Emission Tomography. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peptide receptor radionuclide therapy (PRRT) is an established treatment for somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), with eligibility determined by the Krenning score. While SSTR PET provides greater sensitivity than octreotide scintigraphy, its impact on PRRT eligibility remains unclear. We compared Krenning scores between [111In]octreotide scintigraphy and [68Ga]DOTATOC PET and assessed eligibility under NETTER-1 and NETTER-2 criteria.

Methods

We retrospectively assessed tumor Krenning scores in 115 patients with well-differentiated GEP-NETs who underwent both [111In]octreotide scintigraphy and [68Ga]DOTATOC PET. PRRT eligibility was defined according to NETTER-1 (Krenning ≥2) and NETTER-2 (Krenning ≥3) criteria. Logistic regression identified predictors of Krenning ≥3 on SSTR PET. Quantitative PET analysis was performed for patients with positive baseline [68Ga]DOTATOC PET scans.

Results

Median Krenning scores were higher with SSTR PET than planar imaging (3 [IQR 3–4] vs. 2 [IQR 0–3], p < 10−8). NETTER-1 eligibility increased from 59.1% with planar imaging to 81.7% with PET (p < 10−3), and NETTER-2 from 48.7% to 76.5% (p < 10−4). Among patients eligible on planar imaging, 95.6% (NETTER-1) and 98.2% (NETTER-2) had concordant PET findings. Conversely, 61.7% (NETTER-1) and 55.9% (NETTER-2) of patients ineligible on planar imaging were reclassified as eligible with PET. Metastatic disease was associated with higher SSTR PET uptake (odds ratio 9.5 [95% confidence interval: 2.7–32.8], p < 10−3). SUVmax discriminated patients with Krenning ≥3 using an optimal threshold of 9.2 (AUC 0.93). Conclusions: [68Ga]DOTATOC PET yields higher Krenning scores and increases PRRT eligibility compared with [111In]octreotide scintigraphy. PET may be unnecessary for clearly positive planar studies but identifies additional candidates with borderline or negative planar results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotidePancreatic NeoplasmsPositron-Emission TomographyStomach NeoplasmsOrganometallic CompoundsIntestinal NeoplasmsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedReceptors, SomatostatinRadiopharmaceuticalsAdultRadionuclide Imaging

Stichwörter der Autor:innen

Krenning scoreNeuroendocrine tumorsRadionuclide therapySomatostatin receptor

Substanzen

OctreotideOrganometallic CompoundsReceptors, SomatostatinRadiopharmaceuticalsindium-111-octreotideGa(III)-DOTATOC

Autor:innen und Institutionen

  • Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada.
  • Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Molecular Imaging and Therapy, BC Cancer, Vancouver, British Columbia, Canada.
  • Department of Medical Imaging, University of Toronto, Toronto, Ontario, Canada.
  • Department of Medical Oncology, BC Cancer, Vancouver, British Columbia, Canada, jonathan.loree@bccancer.bc.ca.
  • Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada, jonathan.loree@bccancer.bc.ca.

Zitieren

APA

Fedrigo, R., Harsini, S., Murtha, L., Solar Vasconcelos, J. P., Uribe, C., Wilson, D., Benard, F., Alberts, I., Martineau, P., & Loree, J. M. (2026). Comparison of [ 111 In]octreotide Scintigraphy and [ 68 Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility. Neuroendocrinology, 1-8. https://doi.org/10.1159/000552968

Vancouver

Fedrigo R, Harsini S, Murtha L, Solar Vasconcelos JP, Uribe C, Wilson D, et al. Comparison of [ 111 In]octreotide Scintigraphy and [ 68 Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility. Neuroendocrinology. 2026:1-8. doi:10.1159/000552968

BibTeX
@article{Fedrigo2026,
  author = {Fedrigo, Roberto and Harsini, Sara and Murtha, Luke and Solar Vasconcelos, Joao Paulo and Uribe, Carlos and Wilson, Don and Benard, Francois and Alberts, Ian and Martineau, Patrick and Loree, Jonathan M},
  title = {Comparison of [ 111 In]octreotide Scintigraphy and [ 68 Ga]DOTATOC PET in Gastroenteropancreatic Neuroendocrine Tumors: Concordance of Krenning Scores and Implications for Peptide Receptor Radionuclide Therapy Eligibility},
  journal = {Neuroendocrinology},
  year = {2026},
  pages = {1--8},
  doi = {10.1159/000552968}
}
Kostenlos starten →